Cryoport Systems’ Temperature-Controlled Supply Chain Blog
Learn more from our expert leaders on the latest industry trends, global news, and company updates.
Industry Insights
05/26/2026
Dominic Clarke on Reducing Variability Before it Becomes a Problem
As cell therapy programs advance, the pressure on supply chains doesn’t usually come from a single breaking point. It builds gradually, often in ways that aren’t immediately visible during early development. In a recent episode of Beyond Biotech, the podcast from Labiotech, Dominic Clarke, Vice President of IntegriCell® Technical Operations at Cryoport Systems, shares what that progression looks like.
Industry Insights
05/26/2026
Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break
As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.
Industry Insights
05/26/2026
Cryoport Systems with ISCT on Why Early-Phase Development is Starting to Strain
As advanced therapy programs move faster toward first-in-human (FIH), the pressure isn’t just showing up at commercial scale. It’s appearing much earlier than many teams expect. A recent article Cryoport Systems published with ISCT takes a closer look at that shift, highlighting why execution (not feasibility) is increasingly becoming the constraint in early development.
Industry Insights
05/26/2026
Matthew Plaud on Building Supply Chains that Actually Scale
In a recent conversation with Contract Pharma, Matthew Plaud, COO of IntegriCell® at Cryoport Systems, discussed where advanced therapy supply chains stand today, and where they start to strain as programs move toward commercialization.
Managing the Cold Chain
05/18/2026
Integrate Cryopreservation into the End-to-End Supply Chain
Early‑phase therapy developers rarely think about cryopreservation as a standalone decision. In practice, it sits between collection and manufacturing, shaped by how material moves, how it is documented, and how responsibility is transferred from one group to the next. Despite that reality, cryopreservation is often implemented as a discrete step, managed separately from the rest of the supply chain that supports development execution. That separation may feel manageable early on. It becomes harder to sustain as programs progress.
Managing the Cold Chain
05/12/2026
Why Risk Analysis and Lane Qualification Matter for Regulatory Confidence
As programs move from mid-phase into later development, expectations around compliance change in both scale and tone. Early filings may tolerate explanation, but later submissions expect evidence. Teams preparing for Phase II transitions, Phase III trials, or global commercialization begin to encounter a different level of scrutiny, where regulators are less interested in intent and more focused on whether processes behave consistently under real operating conditions.
Managing the Cold Chain
04/28/2026
A Conversation with Yashu Sarna, President of PDA West Coast Chapter
At this year’s PDA (Parenteral Drug Association) West Coast Chapter conference in Las Vegas, leaders across quality, manufacturing, and operations came together to discuss digital transformation and the evolving demands facing the biopharmaceutical industry. We spoke with Yashu Sarna, President of the PDA West Coast Chapter and Director of Business Development, Cryopreservation at Cryoport Systems, about what the conference revealed, how those insights align with what he’s seeing across the market, and where the industry appears to be heading next.
Managing the Cold Chain
04/21/2026
Validate Cryopreservation as a Defined Input, not a Variable
Most early‑stage cell therapy programs continue to rely on fresh starting material, particularly in pre‑clinical and Phase I development. That reliance is often driven by habit rather than data. Fresh workflows are familiar, but they also embed variability into the earliest experiments, where reproducibility is hardest to restore later. As development pressure increases, teams begin looking for ways to stabilize inputs without introducing new unknowns.
Managing the Cold Chain
04/21/2026
Accelerate Your Trials Without Losing Control With an End-to-End Supply Chain Model
As programs shift from Phase I to Phase II, the workload starts to overlap in new ways. Sample volumes increase as more sites operate in parallel, and activities that once occurred in sequence now run at the same time. The work itself is largely the same, but keeping it coordinated requires more time and attention.Categories
- All (63)
- Industry Insights (28)
- Managing the Cold Chain (58)
- Navigating Logistics (27)
- Patient Access and Awareness (8)
Topics
- Asia
- ATMPs
- Biologics
- BioServices
- Biostorage
- CDMO
- CDMOs
- Cell Therapy
- Clinical Trials
- Cold Chain Management
- Commercialization
- CROs
- Cryopreservation
- Europe
- Fragmentation
- Gene Therapy
- Global Logistics Tracking
- Global Supply Chain Management
- International Shipping
- North America
- Risk Mitigation
- Standards and Compliance
- Supply Chain Management